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SUMMARY – The objective of this study was to evaluate the association between aberrant right 
subclavian artery (ARSA) and chromosomal abnormalities. The study included 5211 women having 
attended our unit for fetal anatomic screening and fetal echocardiography from August 2016 until 
February 2019. After diagnosing ARSA, prenatal invasive testing was discussed with the patients. 
ARSA affected fetus was determined in 57 cases; of these, there were 38 cases of isolated ARSA and 
19 cases of non-isolated ARSA but associated with soft markers and fetal anomalies. Nineteen pa-
tients underwent amniocentesis; Down syndrome was determined in two women, both of them from 
the non-isolated ARSA group, with fetal hydrops, atrioventricular septal defect and esophageal atresia. 
Fifteen of 38 patients who declined prenatal diagnostic testing, accepted karyotype analysis after de-
livery and none of these 15 cases had chromosomal abnormalities. Identification of ARSA should be 
followed by detailed ultrasound examination to ensure that there are no accompanying soft markers 
and/or structural defects. Isolated ARSA may not be an indication for karyotype analysis or 22q11.2 
microdeletions. Non-ARSA implies a strong predictor of aneuploidy, and when additional findings 
are detected, invasive testing should be offered to the parents. The association between isolated ARSA 
and genetic disease should be evaluated in large powered prospective studies.
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Introduction
Aberrant right subclavian artery (ARSA) is identi-
fied by prenatal ultrasound scan in some fetuses. ARSA 
originates from the aortic arch distally instead of bra-
chiocephalic artery as the fourth supra-aortic vessel and 
follows a retrotracheal course towards the right arm in 
the transverse 3-vessel tracheal view. The importance of 
this finding has been a source of debate in recent years, 
as ARSA is claimed to be a marker of some chromo-
somal abnormalities. ARSA is found in approximately 
1%-2% of healthy people according to autopsy series1. 
Its prevalence is estimated to range from 2.9% to 100% 
in cases of Down syndrome2,3. Besides, ARSA is also 
considered to be associated with 22q11.2 deletions4. 
However, evidence is insufficient regarding the associa-
tion between ARSA and these chromosomal condi-
tions. Thus, counseling couples to perform further in-
vestigation with invasive prenatal diagnostic tests may 
be a difficult task in clinical practice.
A meta-analysis examining second trimester soft 
markers for Down syndrome reports on the positive 
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and negative likelihood ratio (LR) of ARSA for triso-
my 21 of 21.4 and 0.71, respectively, and the estimated 
LR for isolated ARSA of 3.945. A study including pa-
tients with ARSA undergoing microarray analysis did 
not find significant differences between ARSA and 
Down syndrome or 22q11.2 deletions, irrespective of 
whether ARSA was an isolated finding or not6. This 
descriptive study aimed to reflect a clinical standpoint 
for ARSA by assessing outcomes of prenatally diag-
nosed ARSA cases at a single institution.
Materials and Methods
This was a retrospective, descriptive cohort study of 
prenatally diagnosed ARSA cases, which was per-
formed at the Department of Perinatology, Health 
Science University Van Training and Research Hospi-
tal, from August 2016 through February 2019. Our 
institution serves as a tertiary referral center in Van 
province, which is one of the low-income regions in 
Turkey. The study was approved by the institutional 
Ethics Committee (ethics approval number: 2019/06 
21/03/2019).
Data on study subjects were obtained from elec-
tronic medical records in which all data are prospec-
tively collected. All ultrasound exams were carried out 
using a Voluson E8 ultrasound machine (GE Health-
care, Milwaukee, USA) with a 4-8MHz transabdomi-
nal probe by a single operator (R. A.), who is a mater-
nal-fetal specialist with extensive experience in per-
forming fetal anatomy scan, as well as fetal echocar-
diography. The study included only ARSA cases 
diagnosed between 16 and 26 weeks of gestation. All 
cases underwent anatomy assessment and fetal echo-
cardiography according to the International Society of 
Ultrasound in Obstetrics and Gynecology (ISUOG) 
guidelines7,8. ARSA cases with no if any soft markers 
or structural defects were assigned as isolated cases, 
whereas ARSA cases with at least one soft marker or 
structural defect were assigned as non-isolated cases.
Identification of ARSA
Aberrant right subclavian artery is one of the non-
specific soft markers for aneuploidies and can be de-
tected on the second-trimester ultrasound. Visualiza-
tion of the right subclavian artery was adopted from 
the technique described by Chaoui et al.9. The aortic 
arch was carefully evaluated to identify ARSA at the 
level of three vessel trachea view in the upper medias-
tinum where it courses between the trachea and the 
spine, and runs towards the right arm on color Dop-
pler.
Genetic counseling and prenatal diagnostic testing
Following detailed genetic counseling, the parents 
of all ARSA cases were offered to undergo a prenatal 
diagnostic test to examine whether Down syndrome 
and/or 22q11.2 microdeletions accompanied current 
pregnancy. Amniocentesis procedure was performed in 
those who consented to do so. The choice of genetic 
test was conventional karyotyping in conjunction with 
fluorescence in situ hybridization (FISH). The option 
of postnatal genetic testing was offered to those who 
declined to have a prenatal diagnostic test. Blood sam-
ples of neonates were used for postnatal genetic assess-
ment.
Descriptive statistics was used on data processing 
and data were expressed as number (percentage) or 
median (minimum-maximum).
Results
During the study period, 5211 women underwent 
ultrasound scan for fetal anatomy survey between 16 
and 26 weeks of gestation. Figure 1 shows flowchart of 
the study. The median gestational age and median ma-
ternal age at diagnosis (min-max) was 21 weeks (range, 
16-26) and 28 years (range, 17-44), respectively. Of 
these, 57 women had an ARSA affected fetus. Of these 
57 cases, 38 had isolated ARSA and 19 had non-iso-
lated ARSA. The rate of ARSA in our study popula-
tion was 1.1% (57/5211).
The following markers or anomalies were identified 
in the non-isolated group: pyelectasis (n=4), hyper-
echogenic bowel (n=4), hyperechogenic intracardiac 
focus (n=4), single umbilical artery (n=1), nuchal fold 
thickness (n=1), short femur plus short humerus (n=1), 
hyperechogenic bowel plus persistent left superior 
vena cava (n=1), ventricular septal defect (VSD) plus 
single umbilical artery (n=1), atrioventricular septal 
defect (AVSD) plus esophageal atresia (n=1) and fetal 
hydrops (n=1).
Nineteen of 57 patients underwent amniocentesis 
after detailed genetic counseling, including 11 in the 
isolated group and eight in the non-isolated group. 
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Karyotyping result was normal in the 11 isolated cases, 
while karyotyping resulted in trisomy 21 in two of 
eight non-isolated cases, one having AVSD plus 
esophageal atresia and another one having fetal hy-
drops.
Thirty-eight patients declined to have prenatal in-
vasive test via amniocentesis. Of these, 15 patients ac-
cepted postnatal genetic testing, which showed 12 of 
them to have isolated ARSA and three of them to 
have non-isolated ARSA. None of these 15 cases had 
karyotype abnormalities based on conventional karyo-
typing in conjunction with FISH. On physical exami-
nation, the remaining 23 cases that did not undergo 
any genetic testing did not show any signs indicative of 
chromosomal abnormalities including Down syn-
drome and 22q11.2 microdeletions.
The overall rate of Down syndrome was 3.5% 
(2/57) in the presence of the finding of ARSA in our 
series. When only cases undergoing genetic testing (34 
out of 57 cases) were included in the analysis, the rate 
of Down syndrome was 5.8% (2/34). Both cases with 
Down syndrome had major structural abnormalities. 
Maternal age in these two cases with trisomy 21 was 
39 and 26 years. Their pregnancies were terminated. 
There was no case with Down syndrome in the isolat-
ed group. The cases tested did not have 22q11.2 micro-
deletions. Table 1 shows clinical and demographic 
characteristics of these cases.
Of 57 cases, 44 had the first or second trimester 
screening test and the remaining 13 cases did not un-
dergo it. The risk of aneuploidy was high in eight of 44 
cases; however, only three of them underwent invasive 
test and Down syndrome was found in two of these 
three cases.
Discussion
The incidence of ARSA was 1.1% in our patient 
population, which resides in a low-income region. This 
rate is similar to the reported incidence rate of ARSA 
in the general population10. There were two Down syn-
drome cases among 57 ARSA cases, translating into a 
rate of 3.5% for Down syndrome. As described above, 
both Down syndrome cases had structural defects, 
with a high risk first trimester combined screening (a 
risk of 1/50). None of the isolated cases had Down 
syndrome. We did not diagnose any cases with 22q11.2 
microdeletions in our series. It seems that further ge-
netic investigation does not contribute to clarifying 
the isolated ARSA cases. Thus, ARSA may be consid-
ered as a variant of normal if found in isolation.
The finding of isolated ARSA implies that there 
are no other identifiable soft markers and structural 
defects during anatomy survey. It has also been pro-
posed that the background risk of aneuploidy in a pa-
tient carrying an ARSA-affected fetus should be eval-
uated before assigning ARSA as an isolated finding. It 
remains elusive whether the finding of isolated ARSA 
Fig. 1. Study flowchart.
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is an indication for performing prenatal invasive test. 
Although earlier studies found an association between 
ARSA and chromosomal abnormalities, they did not 
differentiate isolated ARSA cases from non-isolated 
ones11. Esmer et al. report on 10 Down syndrome cases 
with ARSA, which was in isolation in six of these 10 
cases12. However, of these six cases, five had advanced 
maternal age (≥35) and four had a high-risk screening 
Table 1. Ultrasonographic findings, measurement of nuchal translucency, results of screening tests and pre-postnatal 































































































































































































































































































































GW = gestational week; NT = nuchal translucency; FL = femur length; VSD = ventricular septal defect; SUA = single umbilical artery; 
PLSV = persistent left superior vena cava; AVSD = atrioventricular septal defect; HIF = hyperechogenic intracardiac focus; N = Normal
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test. It is known that the risk of having an aneuploid 
baby was significantly higher in older women com-
pared with younger women, with a 4-fold increase in 
those aged 35-40 years compared with those aged 30-
35 years13. In their study conducted in a high-risk pop-
ulation, Borenstein et al. estimated the identification of 
ARSA in the second trimester to imply a 20-fold in-
crease in the risk of Down syndrome and 13-fold in-
crease in the risk of trisomy 1814. However, their study 
did not provide data whether any of other ultrasound-
based soft markers accompanied ARSA. Paladini et al. 
suggest that detection of ARSA is the third most im-
portant marker for offering prenatal invasive test after 
nasal bone hypoplasia/absence and increased nuchal 
fold. Furthermore, they report ARSA to be the only 
finding in eight of 27 (29.6%) fetuses with Down syn-
drome; however, maternal age and the results of first 
trimester screening test were not provided in their 
study15.
The finding of isolated ARSA has been reported to 
be a poor maker of Down syndrome in several stud-
ies6,15-18. Zalel et al. identified Down syndrome in three 
of 16 fetuses with ARSA; all three cases had at least 
one additional soft marker or structural defect16. Sagi-
Dain et al. identified only one Down syndrome among 
246 isolated ARSA cases according to microarray 
analyses, and the first trimester screening test result 
was 1/65 in this case, with maternal age of 39 years6. 
De León-Luis et al. found 60 cases with ARSA in un-
selected 8781 pregnant women, with ARSA being in 
isolation in 39 cases and non-isolated in 21 cases. They 
did not detect any Down syndrome cases in the iso-
lated group, whereas there were seven Down syndrome 
cases in the non-isolated group19. Similar to our find-
ings, some recent studies also report no aneuploidies 
and pathogenic copy number variants in cases of iso-
lated ARSA based on conventional karyotyping and 
microarray analysis16,18. In support of the existing lit-
erature, both Down syndrome cases had at least one 
additional marker and a high-risk screening result in 
our study. It seems reasonable to define ARSA as an 
isolated finding if there are no other ultrasound-based 
soft markers and structural defects in conjunction with 
a low-background risk. Relevant literature suggests 
that ARSA in isolation as an ultrasound marker may 
not be a finding requiring further work-up. Thus, the 
decision-making process to proceed with prenatal in-
vasive testing should not only hinge on whether the 
finding of ARSA is present or not.
Approximately 10%-15% of all pregnant women 
experience a variety of emotional changes that increase 
the risk of anxiety and depression, which can adversely 
affect both pregnant women and developing fetuses, 
and detection of soft markers during the second tri-
mester fetal anatomic screening examination causes 
anxiety in pregnant women20,21. During prenatal ge-
netic counseling of a couple having a fetus with ARSA, 
the pre-existing risk factors including maternal age, 
result of first trimester combined screening test, and 
other second trimester soft markers should be taken 
into consideration. Isolated soft marker findings ex-
cept for thickened nuchal fold, nasal bone agenesis/
hypoplasia, ARSA and ventriculomegaly, which have a 
high likelihood ratio, are rarely associated with chro-
mosomal or other abnormalities5. Otherwise, the risk 
of aneuploidy is higher whenever more than one 
marker is found. In 2013, a meta-analysis calculated 
the finding of isolated ARSA to increase the risk of 
Down syndrome about 3- to 4-fold, which was based 
on only two studies. In addition, the majority of stud-
ies included in this meta-analysis examined high-risk 
populations5. In 2014, another meta-analysis conclud-
ed that the likelihood ratio of isolated and non-isolat-
ed ARSA was 0 and 35.3 for Down syndrome, respec-
tively. It seems that the conclusion of the latter meta-
analysis more accurately reflects actual situation re-
garding the association between ARSA and Down 
syndrome, as it included a higher number of studies 
compared with the former one19. In 2015, Scala et al. 
suggested in their meta-analysis that the background 
risk and other ultrasound-based markers should be as-
sessed before making decision to perform invasive 
testing for chromosomal abnormalities10.
As regards other chromosomal aberrations, 22q11.2 
microdeletions are considered to be associated with 
ARSA. In particular, concern has been raised regard-
ing a link between conotruncal anomalies secondary to 
22q11.2 microdeletions and ARSA. However, it re-
mains speculative whether there is a need for further 
work-up to investigate 22q11.2 microdeletions4,18,22. 
McElhinney et al. report that chromosome 22q11.2 
deletions were found in 2/7 (29%) patients with iso-
lated ARSA and noassociated intracardiac defects4. 
Pico et al. and Rembouskos et al. report on ARSA to 
accompany two cases with 22q11.2 deletions; however, 
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both had additional cardiac and extra-cardiac find-
ings23,24. Sagi-Dain et al. analyzed 246 isolated ARSA 
cases for chromosome 22q11.2 deletions by microarray 
analysis and there was no case with 22q11 deletions 
among them6. Maya et al. demonstrated that ARSA 
was strongly associated with 22q11.2 deletion syn-
drome if accompanying enlarged nuchal translucency 
(NT; >4 mm), VSD, right aortic arch, clubfoot, echo-
genic intracardiac focus, and high-risk screening for 
trisomy 2117. Our cohort did not have any cases with 
22q11.2 microdeletions and none of the patients with 
ARSA had conotruncal anomalies. The fact that the 
incidence of DiGeorge syndrome is approximately 3 
per 10,000 plays a limiting factor in revealing its asso-
ciation with ARSA. Thus, more work is needed to ex-
plore this association.
Cell-free DNA (cfDNA) screening is the most ac-
curate form of screening testing for trisomy 2125. 
However, it is not recommended for microdeletion 
syndromes26. As reducing the risk of miscarriage de-
pends on invasive tests, cfDNA in maternal blood 
might be offered for common aneuploidies but not for 
22q11.2 microdeletion.
Our study had several limitations. One of the limi-
tations was that it was retrospectively conducted. The 
second limitation was the inability to perform micro-
array analysis for further genetic investigation because 
the Ministry of Health in Turkey only covered con-
ventional karyotyping and FISH as diagnostic genetic 
tests, and the study included a low-income patient 
population. Third, the follow up was based on physical 
examination. Fourth, our sample size did not allow us 
to make definitive recommendation for or against per-
forming an invasive test in case of isolated ARSA.In 
addition, genetic information could not be obtained 
for 23 fetuses with ARSA as their parents denied ge-
netic testing. Although physical examinations of all 
neonates that did not undergo genetic testing were 
within the normal range, 22q11.2 microdeletions 
could not be ruled out with certainty as the typical fea-
tures of 22q11.2 microdeletions, such as facial dys-
morphism and neurodevelopmental disorder, may not 
be seen in the neonatal period.
In conclusion, a detailed ultrasound survey includ-
ing fetal echocardiography is the crucial part of assess-
ment in cases of ARSA. The finding of non-isolated 
ARSA seems to be a risk-modifying factor for Down 
syndrome. Thus, complete prenatal genetic work-up 
should be offered to the expectant parents in the pres-
ence of accompanying soft marker and/or structural 
defect, advanced maternal age, or a high-risk screening 
result. However, the decision to proceed with invasive 
diagnostic testing for aneuploidy is less certain in low-
risk pregnancies if ARSA is found in isolation. Cell-
free DNA test may be an alternative to invasive test in 
these cases. Further studies are still needed to fill the 
knowledge gap regarding the association between iso-
lated ARSA and aneuploidy.
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Sažetak
PRENATALNA IDENTIFIKACIJA IZOLIRANE ABERANTNE POTKLJUČNE ARTERIJE:  
JE LI POTREBNA DALJNJA GENETSKA OBRADA?
R. Ayaz, E. Göktas, G. Turkyilmaz i M. Resit Asoglu
Cilj ovoga istraživanja bio je procijeniti udruženost aberantne desne potključne arterije (ADPA) i poremećaja kromoso-
ma. Istraživanje je obuhvatilo 5211 žena koje su posjetile našu jedinicu za anatomski probir i fetalnu ehokardiografiju od 
kolovoza 2016. do veljače 2019. godine. Nakon što je dijagnosticirana ADPA sa ženama se razgovaralo o prenatalnom inva-
zivnom testiranju. Fetalna ADPA utvrđena je u 57 slučajeva, uključujući 38 slučajeva izolirane ADPA i 19 slučajeva ne-izo-
lirane ADPA, ali udružene s „mekim“ biljezima i fetalnim anomalijama. Devetnaest žena podvrgnuto je amniocentezi. 
Downov sindrom utvrđen je kod dvije žene, obje iz skupine s ne-izoliranom ADPA, s fetalnim hidropsom, atrioventrikul-
skim septalnim defektom i atrezijom jednjaka. Petnaest od 38 žena koje su odbile prenatalno dijagnostičko testiranje prihva-
tilo je analizu kariotipa nakon porođaja i nijedna od njih nije imala kromosomne poremećaje. Nakon identificiranja ADPA 
treba uslijediti podroban ultrazvučni pregled kako bismo bili sigurni da ne postoje prateći „meki“ biljezi i/ili strukturni de-
fekti. Izolirana ADPA ne mora biti indikacija za analizu kariotipa ili mikrodelecije 22q11.2. Ne-ADPA snažno upućuje na 
aneuploidiju, a kad se dobiju dodatni nalazi tada treba roditeljima ponuditi invazivno testiranje. Udruženost izolirane ADPA 
i genetske bolesti treba procijeniti u velikim i valjanim prospektivnim studijama.
Ključne riječi: Aberantna desna potključna arterija; Mikrodelecija 22q11.2; Aneuploidija; Trisomija 21; Prenatalna dijagnostika
